<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175731</url>
  </required_header>
  <id_info>
    <org_study_id>2017037-QILU</org_study_id>
    <nct_id>NCT03175731</nct_id>
  </id_info>
  <brief_title>PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)</brief_title>
  <acronym>PPIs</acronym>
  <official_title>A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanjing Gao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver&#xD;
      cirrhosis. Half of participants will receive PPI, while the other half will receive a&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPIs can inhibit parietal cell H+/K+-ATPase and reduce secretion of gastric acid. PPIs can&#xD;
      promote platelet aggregation and stabilize the formation of fibrin thrombosis by maintaining&#xD;
      the high pH environment in the stomach and inactivating pepsin. The effect of PPIs on&#xD;
      ulcerative upper gastrointestinal bleeding was confirmed but it is not clear whether PPIs is&#xD;
      applicable in esophagogastric variceal bleeding whose etiology and bleeding position are&#xD;
      different from ulcerative upper gastrointestinal bleeding. There is lack of consensus and&#xD;
      sufficient evidences to support to use PPIs in esophagogastric variceal bleeding in cirrhotic&#xD;
      patients universally. Nevertheless, the use of PPIs in liver cirrhotic patients with&#xD;
      gastroesophageal varices is common.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variceal Bleeding Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary endpoint was variceal bleeding, which was defined as hematemesis or melena from endoscopically proven GEVs, in the absence of any other lesion that might explain the bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>8 weeks</time_frame>
    <description>Prognosis of esophagogastric variceal bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Eventsafter Endoscopic Therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Advers events caused by endoscopic therapy, including chest pain, dysphagia, fever and so on</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Proton Pump Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton Pump Inhibitors</intervention_name>
    <description>Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
    <arm_group_label>Proton Pump Inhibitors</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of cirrhosis&#xD;
&#xD;
          -  GEVs was diagnosed by endoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute gastrointestinal bleeding need emergency surgery&#xD;
&#xD;
          -  Acid-related disease, such as peptic ulcer disease or gastroesophageal reflux diseases&#xD;
             (GERD)&#xD;
&#xD;
          -  Hepatocellular carcinoma (HCC) or other malignant tumor&#xD;
&#xD;
          -  History of esophagus, stomach or liver surgery&#xD;
&#xD;
          -  Child-Pugh C and can't be improved to Child-Pugh A or B&#xD;
&#xD;
          -  Preparing to be pregnant, pregnant or breast feeding&#xD;
&#xD;
          -  Allergic to PPIs(proton pump inhibitors) or intolerable&#xD;
&#xD;
          -  Cannot provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanjing /A Gao, PhD.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital,Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology,Qilu Hospital,Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <results_first_submitted>May 13, 2021</results_first_submitted>
  <results_first_submitted_qc>May 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2021</results_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Yanjing Gao</investigator_full_name>
    <investigator_title>Vice presidengt of Department of Gastroenterology of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal varices</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03175731/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Proton Pump Inhibitors</title>
          <description>Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Proton Pump Inhibitors: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Placebo: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Proton Pump Inhibitors</title>
          <description>Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Proton Pump Inhibitors: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Placebo: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="53"/>
                    <count group_id="B3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="10.0"/>
                    <measurement group_id="B2" value="54.2" spread="10.6"/>
                    <measurement group_id="B3" value="53.8" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="53"/>
                    <count group_id="B3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="53"/>
                    <count group_id="B2" value="53"/>
                    <count group_id="B3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Variceal Bleeding Events</title>
        <description>The primary endpoint was variceal bleeding, which was defined as hematemesis or melena from endoscopically proven GEVs, in the absence of any other lesion that might explain the bleeding.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitors</title>
            <description>Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Proton Pump Inhibitors: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Placebo: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Variceal Bleeding Events</title>
          <description>The primary endpoint was variceal bleeding, which was defined as hematemesis or melena from endoscopically proven GEVs, in the absence of any other lesion that might explain the bleeding.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Prognosis of esophagogastric variceal bleeding.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitors</title>
            <description>Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Proton Pump Inhibitors: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Placebo: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Prognosis of esophagogastric variceal bleeding.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Eventsafter Endoscopic Therapy</title>
        <description>Advers events caused by endoscopic therapy, including chest pain, dysphagia, fever and so on</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton Pump Inhibitors</title>
            <description>Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Proton Pump Inhibitors: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Placebo: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Eventsafter Endoscopic Therapy</title>
          <description>Advers events caused by endoscopic therapy, including chest pain, dysphagia, fever and so on</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks after endoscopic therapy.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Proton Pump Inhibitors</title>
          <description>Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Proton Pump Inhibitors: Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.&#xD;
Placebo: Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Gao</name_or_title>
      <organization>Qilu Hospital of Shandong University</organization>
      <phone>+86-531-82169386</phone>
      <email>gaoyanjing@sdu.edu.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

